Pulmonary Arterial Hypertension (PAH)
Conditions
Brief summary
Change from baseline in Pulmonary Vascular Resistance (PVR)
Detailed description
Occurrence of Treatment-Emergent Adverse Events (TEAEs), Severity of TEAEs, Change from baseline in circulating N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) concentrations, Change from baseline in mean pulmonary artery pressure, Change from baseline in cardiac output, Change from baseline in cardiac index, Change from baseline in right atrial pressure, Change from baseline in 6-Minute Walk Distance (6MWD), Concentrations of functional REGN13335 in plasma, Concentrations of total soluble Platelet-Derived Growth Factor-B (PDGF-B) ligands in plasma
Interventions
DRUGPlacebo to REGN13335
DRUGREGN13335
Sponsors
Regeneron Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in Pulmonary Vascular Resistance (PVR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of Treatment-Emergent Adverse Events (TEAEs), Severity of TEAEs, Change from baseline in circulating N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) concentrations, Change from baseline in mean pulmonary artery pressure, Change from baseline in cardiac output, Change from baseline in cardiac index, Change from baseline in right atrial pressure, Change from baseline in 6-Minute Walk Distance (6MWD), Concentrations of functional REGN13335 in plasma, Concentrations of total soluble Platelet-Derived Growth Factor-B (PDGF-B) ligands in plasma | — |
Outcome results
None listed